Some years ago, a patient came to see me who had recently survived a heart attack. He was 53 years old. Non-smoker. Healthy weight. Exercised regularly. His LDL — the cholesterol number most doctors treat as the primary cardiovascular indicator — was 72 mg/dL. His cardiologist had noted, with some confusion, that his lipids looked fine and couldn't really explain his heart attack. His GP had been equally puzzled. Nobody, in years of routine check-ups, had found anything to worry about.

We ordered a full panel. When his Lp(a) came back at 178 nmol/L — well into the 95th percentile — the mystery was solved immediately. He had been carrying a significant, heritable cardiovascular risk for decades. Nobody had looked for it. And because nobody had looked for it, nobody had done anything about it.

Even in 2026, that scenario is more common than it should be. Lipoprotein(a) — abbreviated Lp(a), pronounced "L-P-little-a" — is one of the most well-studied cardiovascular risk factors we have. The evidence linking elevated Lp(a) to heart attack and stroke is large, robust, and causal. Yet it remains absent from most standard lipid panels, from most routine check-ups, and from most doctors' working vocabulary outside of specialist cardiology.

Elevated Lp(a) affects approximately one in five people globally — and the vast majority of them have never been told.

A particle with three distinct weapons

To understand why Lp(a) matters, it helps to understand what it actually is — and why it is not simply another form of LDL cholesterol.

Lp(a) is a lipoprotein particle circulating in the bloodstream with the same lipid-carrying core as LDL. But it has one critical structural difference: an additional protein called apolipoprotein(a), attached to its surface. That structural addition gives Lp(a) three distinct mechanisms of harm that LDL alone does not share.[5]

First, like LDL, Lp(a) is atherogenic — it deposits in artery walls, contributes to plaque formation, and drives the progressive narrowing of coronary vessels that precedes most heart attacks.

Second, and more distinctively, Lp(a) is prothrombotic. Apolipoprotein(a) has a structural resemblance to plasminogen — the protein responsible for dissolving blood clots. Lp(a) competes with plasminogen for binding sites, interfering with the body's natural clot-clearing mechanism. At elevated concentrations, this increases the risk of blood clots and thrombotic events: not just slow arterial narrowing, but acute clot formation.[5]

Third, Lp(a) particles carry oxidized lipids on their surface. These lipids trigger inflammation in the blood vessels and promote the progression of both coronary artery disease and calcific aortic valve stenosis.[4]

It is this combination — atherogenic, prothrombotic, and pro-inflammatory, operating simultaneously — that makes elevated Lp(a) a qualitatively different risk than elevated LDL. It explains why a patient can have perfectly managed LDL cholesterol and still face a meaningfully elevated risk of a cardiovascular event.

Why your lifestyle cannot fix it — and why that changes everything

The single most important thing to understand about Lp(a) is that it is almost entirely determined by genetics. Specifically, by inherited variants in the LPA gene, which governs the size and production rate of apolipoprotein(a). Approximately 90% of the variation in Lp(a) levels between people is heritable — making it one of the most genetically determined cardiovascular risk factors known.[3]

This matters for two reasons, and they pull in opposite directions.

On one hand, it means that knowing your Lp(a) is genuinely informative. Unlike LDL — which fluctuates with diet, weight, and medications — your Lp(a) is essentially stable across your adult life. A single measurement, at any age, gives you a reliable picture of a lifelong risk profile. You only need to test once.

On the other hand, it means that the standard advice given to cardiovascular risk patients — exercise more, eat less saturated fat, lose weight, take a statin — while important, does not address elevated Lp(a). Statins do not lower Lp(a); in some patients, they raise it modestly.[3] A patient who follows every piece of guideline-concordant lifestyle advice can still carry an unmanaged, elevated Lp(a) risk year after year. Doing everything right is not enough, if the right things have no effect on this particular risk factor.

The blind spot in standard cardiovascular risk scoring

The two most widely used cardiovascular risk calculators in clinical practice — the Framingham Risk Score and the ACC/AHA Pooled Cohort Equations — do not include Lp(a). Neither does the European SCORE system in its standard form. This creates a systematic blind spot: a patient with elevated Lp(a) and otherwise unremarkable lipids will be categorised as low or intermediate risk by every standard tool, while their actual cardiovascular risk is substantially higher.

The evidence documenting this gap is substantial. A landmark meta-analysis by the Emerging Risk Factors Collaboration, analysing data from 36 prospective studies and more than 126,000 participants, found that elevated Lp(a) was independently associated with increased risk of coronary heart disease and stroke, even after adjusting for LDL, HDL, triglycerides, and all other standard risk factors.[2] The relationship held at all levels of LDL — meaning there is no LDL threshold below which high Lp(a) becomes clinically irrelevant.

Critically, a Mendelian randomization study published in JAMA established the relationship as causal, not merely associative. Individuals who inherited genetic variants that raise Lp(a) had a corresponding increase in myocardial infarction risk — confirming that Lp(a) itself drives cardiovascular disease, and is not simply a bystander marker.[1]

Guideline bodies have been slow to respond. The 2018 ACC/AHA cholesterol guidelines moved Lp(a) into the category of "risk-enhancing factors."[6] The 2019 ESC/EAS dyslipidaemia guidelines went further, recommending that Lp(a) be measured at least once in every adult's lifetime to identify those at very high heritable risk.[7] Most physicians have not yet translated that recommendation into practice.

What changes when you know your number?

The clinical value of Lp(a) measurement is not academic. It directly changes the decisions a physician will make. For patients with elevated Lp(a), the following interventions all shift in their clinical calculus:

01
PCSK9 inhibitors become more compelling — for two reasons
Monoclonal antibodies that inhibit PCSK9 (evolocumab, alirocumab) are primarily known for dramatically lowering LDL. But they also reduce Lp(a) by approximately 25–30% — the most meaningful Lp(a) reduction currently available in clinical practice. The FOURIER trial (evolocumab) and the ODYSSEY OUTCOMES trial (alirocumab) both showed that patients with higher baseline Lp(a) derived proportionally greater cardiovascular benefit from PCSK9 inhibition. For a patient with elevated Lp(a) and borderline LDL, the case for a PCSK9 inhibitor is substantially stronger than standard guidelines alone would suggest.[8][9]
02
Statin decisions become more nuanced
Statins are still appropriate for LDL management in most patients — but knowing a patient has high Lp(a) changes the intensity rationale and raises a specific clinical question: statins may modestly increase Lp(a) in some patients. For most people, the LDL benefit vastly outweighs any Lp(a) effect. But in a patient at the margin of a statin decision, Lp(a) status provides important context that a standard LDL reading cannot.
03
Coronary calcium scoring becomes a priority
A coronary artery calcium (CAC) score is a powerful independent predictor of cardiovascular events. For intermediate-risk patients with elevated Lp(a), imaging to quantify plaque burden helps define the urgency of intervention — and helps explain to a patient who feels well and has "normal" cholesterol why more aggressive treatment is justified.
04
Aortic valve monitoring enters the picture
Lp(a) is now recognised as a causal risk factor for calcific aortic valve stenosis — not just coronary disease. The 2022 European Atherosclerosis Society consensus explicitly highlights this link, noting that the oxidized phospholipids carried by Lp(a) particles appear to drive valve calcification.[4] For patients with elevated Lp(a), periodic echocardiographic monitoring of aortic valve function becomes clinically reasonable.
05
Family screening becomes indicated
Because Lp(a) is genetically determined, a high result in one person is a signal about the entire family. First-degree relatives have a significantly elevated probability of similar Lp(a) elevation. Identifying it early — before a cardiac event — is exactly the window in which the clinical interventions available today and the therapies arriving in the near future can do the most good.

The drugs being developed specifically to target Lp(a)

For most of Lp(a)'s clinical history, there was a frustrating asymmetry: strong evidence that elevated Lp(a) was harmful, but no therapeutic tools to address it directly. That is now changing, with four classes of Lp(a)-specific drugs in late-stage development — all achieving reductions in Lp(a) that were unimaginable even five years ago.

Drug Mechanism Lp(a) reduction Phase / Trial
Pelacarsen
Antisense oligonucleotide
 Targets LPA gene mRNA in hepatocytes; reduces Lp(a) production at source ~80% Phase 3 HORIZON trial — cardiovascular outcomes primary endpoint[10]
Olpasiran
Small interfering RNA (siRNA)
 RNA silencing of LPA gene; quarterly or twice-yearly dosing ≥90% Phase 2 OCEAN(a) — NEJM 2022 — outcomes trial underway[11]
Muvalaplin
Oral small molecule
 Disrupts apo(a)–apoB bond; prevents Lp(a) particle assembly; first oral agent ~65–80% Phase 2 results — JAMA 2023[12]
Lepodisiran
Long-duration siRNA (Eli Lilly)
 GalNAc-conjugated siRNA silencing hepatic LPA mRNA; single injection active for up to 12 months ~94% Phase 2 — NEJM 2025 — Phase 3 ACCLAIM-Lp(a) underway[13]

The clinical significance of this pipeline cannot be overstated. If any of these agents demonstrates a cardiovascular outcomes benefit in Phase 3 trials — which is the central clinical question all four programmes are designed to answer — Lp(a) will immediately become one of the most actionable biomarkers in preventive cardiology.[10][11][13]

Not knowing your Lp(a) doesn't make the risk disappear. It makes you unaware of it — and unpositioned to act when the first targeted therapies are approved.

This creates a specific and time-sensitive argument for testing now. A patient who does not know their Lp(a) today will not be in a position to access targeted Lp(a) therapy the moment those drugs are approved — because their physician will have no indication to prescribe it. The window between now and approval is the right moment to identify which patients are candidates. There are also ongoing opportunities to enrol in clinical trials targeting Lp(a) and cardiovascular outcomes.

Who should be tested, and when

The short answer, per the current European Atherosclerosis Society consensus, is: everyone, once.[4] Because Lp(a) is genetically determined and stable across adult life, a single measurement at any age gives reliable, lifelong information about this component of cardiovascular risk. There is no clinical justification for not knowing a number that is this informative and this rarely changes. Certain groups have the most to gain from testing promptly:

The test itself is a single blood draw. It is not expensive. The result is stable — you need not repeat it. The clinical return on a single Lp(a) measurement, in the right patient, is potentially a heart attack that doesn't happen.

The marker standard care continues to overlook

Lp(a) is not a niche marker or an emerging theory. The evidence supporting its role in cardiovascular disease is decades old, robust, and causal. Guidelines from both the European and American cardiology communities have recommended its measurement. A wave of powerful new therapies targeting it specifically are in late-stage trials.

And yet the majority of people who carry an elevated Lp(a) — roughly one in five of the global population — have never been told. Their doctors have never ordered the test. It is not on the standard panel. It is not in the workflow.

Preventive medicine at its most fundamental level is about finding what standard care doesn't look for, before it becomes a problem you have to manage instead of prevent. Lp(a) is that biomarker, in cardiovascular disease, for approximately 1.4 billion people in the world today. Most of them don't know it.

Breeoot

Your Lp(a) is one test away.

Breeoot measures Lp(a) as part of every member's initial biomarker panel — and interprets it in the full clinical context of your cardiovascular risk profile. Schedule a consultation to understand what your numbers mean.

Schedule a consultation →
References
  1. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.
  2. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.
  3. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
  4. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946.
  5. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
  6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
  7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
  8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
  9. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
  10. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255.
  11. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a). N Engl J Med. 2022;387(20):1855–1864.
  12. Nicholls SJ, Nissen SE, Bhatt DL, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation. JAMA. 2023;330(11):1042–1053.
  13. Nissen SE, Wolski K, Scrimgeour AC, et al. Lepodisiran — a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673–1684.